SCHEMBL5159751

SCHEMBL5159751

NC(=O)CC(=O)c1ccccn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.55
CES1 P23141 1/20 0.55
LMNA P02545 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
NAPRT Q6XQN6 1/20 0.53
P4HTM Q9NXG6 1/20 0.53
ALDH1A1 P00352 1/20 0.52
CTNNB1 P35222 5/20 0.50
WNT3A P56704 3/20 0.50
GRM4 Q14833 1/20 0.50
HDAC3 O15379 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC10 Q969S8 1/20 0.49
HDAC11 Q96DB2 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
HDAC9 Q9UKV0 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL253276 0.88 CES2 (0.64) CES2CES1LMNAL3MBTL1NAPRT
SCHEMBL29355245 0.88 CES2 (0.64) CES2CES1LMNAL3MBTL1NAPRT
SCHEMBL8115339 0.85 CES2 (0.52) CES2CES1LMNAL3MBTL1NAPRT
SCHEMBL33721999 0.84 CES2 (0.59) CES2CES1LMNAL3MBTL1NAPRT
SCHEMBL2544523 0.84 CES2 (0.59) CES2CES1LMNAL3MBTL1NAPRT
SCHEMBL9493294 0.82 LMNA (0.61) CES2CES1LMNAL3MBTL1NAPRT
SCHEMBL29740682 0.81 ALDH1A1 (0.62) CES2CES1LMNAL3MBTL1NAPRT
SCHEMBL1360847 0.81 ALDH1A1 (0.62) CES2CES1LMNAL3MBTL1NAPRT
Methylene Chloride SCHEMBL28230710 0.81 HDAC3 (0.57) CES2CES1LMNAL3MBTL1NAPRT
SCHEMBL109657 0.80 HDAC3 (0.61) CES2CES1LMNAL3MBTL1NAPRT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO CES2 441/4885CES1 382/4885LMNA 3165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.